As of 2024-12-14, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -7.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 4,076.71 mil USD. RARE's TTM EBITDA according to its financial statements is -564.23 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.1x | 13.8x |
| Forward P/E multiples | 15.2x - 21.1x | 15.5x |
| Fair Price | (91.25) - (90.39) | (87.88) |
| Upside | -299.3% - -297.4% | -292.0% |
| Date | EV/EBITDA |
| 2024-12-12 | -7.41 |
| 2024-12-11 | -7.73 |
| 2024-12-10 | -7.77 |
| 2024-12-09 | -7.80 |
| 2024-12-06 | -7.81 |
| 2024-12-05 | -7.48 |
| 2024-12-04 | -7.44 |
| 2024-12-03 | -7.37 |
| 2024-12-02 | -7.52 |
| 2024-11-29 | -7.53 |
| 2024-11-27 | -7.61 |
| 2024-11-26 | -7.48 |
| 2024-11-25 | -7.44 |
| 2024-11-22 | -7.46 |
| 2024-11-21 | -7.26 |
| 2024-11-20 | -7.33 |
| 2024-11-19 | -7.12 |
| 2024-11-18 | -6.90 |
| 2024-11-15 | -7.06 |
| 2024-11-14 | -7.53 |
| 2024-11-13 | -7.70 |
| 2024-11-12 | -7.56 |
| 2024-11-11 | -8.04 |
| 2024-11-08 | -7.97 |
| 2024-11-07 | -7.99 |
| 2024-11-06 | -8.00 |
| 2024-11-05 | -8.27 |
| 2024-11-04 | -8.09 |
| 2024-11-01 | -8.08 |
| 2024-10-31 | -8.08 |
| 2024-10-30 | -8.22 |
| 2024-10-29 | -8.37 |
| 2024-10-28 | -8.42 |
| 2024-10-25 | -8.54 |
| 2024-10-24 | -8.70 |
| 2024-10-23 | -8.68 |
| 2024-10-22 | -8.70 |
| 2024-10-21 | -8.65 |
| 2024-10-18 | -8.94 |
| 2024-10-17 | -9.02 |
| 2024-10-16 | -9.18 |
| 2024-10-15 | -9.08 |
| 2024-10-14 | -8.93 |
| 2024-10-11 | -8.75 |
| 2024-10-10 | -8.55 |
| 2024-10-09 | -8.47 |
| 2024-10-08 | -8.46 |
| 2024-10-07 | -8.31 |
| 2024-10-04 | -8.54 |
| 2024-10-03 | -8.51 |